The US metered dose inhaler market is anticipated to grow at a substantial rate of around 2.0% during the forecast period. The major factors that are contributing significantly to the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of Metered Dose Inhaler market in the US. Further, the increasing demand for inhaler due to increasing COPD and asthma patients in the US has endorsed the approval of cohesive reimbursement policies in the US, is further fueling the growth of the market. The US the major market in the North American region due to greater healthcare expenditure and a higher prevalence rate of respiratory diseases.
The US metered dose inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators inhaler are analyzed. The preventive metered dose inhaler segment led the global metered dose inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing metered dose inhalers to cater to a wide range of customers within the region and across the globe. The major players of the US inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp. (Propeller Health), Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Research Methodology
The market study of the US metered dose inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary Sources Include:
The report is intended for metered dose inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. The US Metered Dose Inhaler Market Research and Analysis by Type
2. The US Metered Dose Inhaler Market Research and Analysis by Application
3. The US Metered Dose Inhaler Market Research and Analysis by End-User
The Report covers:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. US Metered Dose Inhaler Market by Type
5.1.1. Preventive Dry Powdered Inhaler
5.1.2. Reliever Dry Powdered Inhaler
5.1.3. Long Acting Bronchodilators Inhaler
5.2. US Metered Dose Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. US Metered Dose Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics
6. Company Profiles
6.1. 3M Co.
6.2. Acorda Therapeutics, Inc.
6.3. Adamis Pharmaceuticals Corp.
6.4. Adherium Ltd.
6.5. Aradigm Corp.
6.6. AstraZeneca PLC
6.7. Boehringer Ingelheim International GmbH
6.8. Drive Devilbiss Healthcare LLC
6.9. GlaxoSmithKline PLC
6.10. Koninklijke Philips N.V.
6.11. Manta Devices LLC
6.12. Novartis AG
6.13. Omron Healthcare Inc.
6.14. ResMed Corp.
6.15. Pulmatrix Inc.
6.16. Savara, Inc.
6.17. Sunovion Pharmaceuticals
6.18. Teva Pharmaceuticals Industries Ltd.
1. US METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. US METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
3. US METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)
1. US METERED DOSE INHALER MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. US METERED DOSE INHALER MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
3. US METERED DOSE INHALER MARKET SHARE BY END-USER, 2018 VS 2025 (%)